Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide) is a novel small-molecule survivin suppressant that induces the down-regulation of survivin and exhibits potent antitumor activity in nude mice bearing human hormone refractory prostate carcinoma cell line PC-3. Although YM155, which has a cationic moiety in its structure, is influxed into its pharmacologically effective site (cancer cells) and one of its eliminating organs (hepatocytes) in a transporter-mediated manner, the mechanism seems to be different between the two cell types. The other eliminating organ is the kidney. In this study, the transport of [(14)C]YM155 was characterized by using human embryonic kidney 293 cells expressing organic cation transporter 1 (OCT1/SLC22A1), OCT2 (SLC22A2), and OCT3 (SLC22A3). YM155 inhibited the uptake of a typical substrate [(3)H]1-methyl-4-phenylpyridinium via OCT1, OCT2, and OCT3 with IC(50) values of 23.8, 15.9, and 108 microM, respectively. The time- and saturable concentration-dependent uptake of [(14)C]YM155 was observed in cells expressing OCT1 and OCT2 with K(m) values of 22.1 and 2.67 microM, respectively, but not in cells expressing OCT3. By taking into consideration the tissue distribution and localization of each transporter, these results suggest that, in humans, YM155 is taken up from the blood into hepatocytes and proximal tubular cells via OCT1 and OCT2, respectively. The comparison of the IC(50) values of OCT inhibitors and K(m) values for the uptake of YM155 into cells expressing OCTs with those into cancer cell lines indicated that transporter(s) other than OCT1 and OCT2 are involved in the uptake of YM155 into cancer cell lines.
Minematsu
Tsuyoshi
T
Astellas Pharma Inc., 2-1-6, Kashima, Yodogawa-ku, Osaka-shi, Osaka 532-8514 Japan. tsuyoshi.minematsu@jp.astellas.com
Iwai
Megumi
M
Umehara
Ken-Ichi
K
Usui
Takashi
T
Kamimura
Hidetaka
H
D015655:1-Methyl-4-phenylpyridinium / Q000378:metabolism; D001667:Binding, Competitive; D055162:Biocatalysis; D002460:Cell Line; D006801:Humans; D007093:Imidazoles / Q000378:metabolism*; D051034:Inhibitor of Apoptosis Proteins; D007700:Kinetics; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors*; D009285:Naphthoquinones / Q000378:metabolism*; D027701:Organic Cation Transport Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D027702:Organic Cation Transporter 1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D000075102:Organic Cation Transporter 2; D004364:Pharmaceutical Preparations / Q000378:metabolism; D000077022:Survivin; D014162:Transfection; D000099254:Organic Cation Transporter 3
D015655:1-Methyl-4-phenylpyridinium; D007093:Imidazoles; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009285:Naphthoquinones; D027701:Organic Cation Transport Proteins; D027702:Organic Cation Transporter 1; D000075102:Organic Cation Transporter 2; D004364:Pharmaceutical Preparations; D000077022:Survivin; D000099254:Organic Cation Transporter 3; C107489:BIRC5 protein, human; C491013:SLC22A2 protein, human; C523798:sepantronium